"Failure to Generate HIV-1 Resistance In Vitro to the Antisense Therapeutic Agent GEM 91."

According to an abstract presented by the authors to the 2nd National Conference on Human Retroviruses and Related Infections, held January 29 - February 2, 1995, in Washington, DC, "GEM 91 is an antisense phosphorothioate complementary to the genomic RNA packaging site and gag initiation site of HIV-1. This agent has potent antiviral activity in vitro against a variety of strains of HIV-1 and it is presently in clinical evaluation as a possible therapeutic for HIV infection. In this study we examined the ability of HIV-1 to generate escape mutants with reduced sensitivity to GEM 91 by performing sequential passages of the virus in the presence of inhibitor. CEM-SS cells were...

Want to see the full article?

• Purchase this article for only $3.00